A phase IV, randomized, multi-center, open-label study to evaluate patient preference of Movantik versus Polyethylene Glycol 3350 for Opioid-Induced Constipation (OIC) treatment. Study will last a total of 7 weeks and require 5 office visits.
Qualified Participants Must:
Be between 18 and 84 years of age
Have constipation caused by pain medication. (OIC)
Be currently using pain medication for 1 month or longer and experiencing chronic constiption
Qualified Participants May Receive:
Open label OIC medication, study related exams and compensation at every visit